Compare Abeona Therapeutics Inc (ABEO) vs Amplitude Inc (AMPL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Amplitude Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Amplitude Inc trades at $8.76 (market cap $1.21B). The key difference: Amplitude Inc is far larger — about 3.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Amplitude Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | AMPL | |
|---|---|---|
Market Cap | $373.32M | $1.21B |
Sector | Health | Technology |
52-Week High | $7.23 | $13.29 |
52-Week Low | $4.17 | $5.61 |
Enterprise Value | $228.22M | $1.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Amplitude (AMPL) trades at $9.16, up 3.62% on the day, with a bullish technical signal from moving averages. Revenue growth is solid at $343M in 2025, but net losses persist at -$89M. Analyst consensus is 66.7% buy with a $9.00 target. Recent news highlights improving fundamentals but also legal investigations.
The outlook is mixed: strong revenue growth and analyst support offer upside, but profitability challenges and legal risks pose headwinds. Investors should weigh the bullish technicals and growth potential against ongoing losses and regulatory scrutiny for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →
